share_log

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Lowers Price Target to $34

Benzinga ·  Aug 12, 2023 01:10

HC Wainwright & Co. analyst Edward White reiterates Cullinan Oncology (NASDAQ:CGEM) with a Buy and lowers the price target from $49 to $34.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment